Drug Name:
PANDEL Rx
Generic Name and Formulations:
Hydrocortisone probutate 0.1%; crm.
Company:
PharmaDerm
Therapeutic Use:
Indications for PANDEL:
Corticosteroid-responsive dermatoses.
Adult:
≥18yrs: apply thin film to affected area 1–2 times daily. Discontinue when control is achieved. Reassess if no improvement within 2 weeks.
Children:
<18yrs: not established.
Warnings/Precautions:
Avoid near or around eyes, face, underarms, groin areas. Occlude only if necessary. Not for diaper dermatitis; do not use in diaper area. Evaluate for HPA axis suppression periodically (esp. in prolonged use, application to large surface area, use of occlusive dressings, impaired skin, or in children); discontinue or reduce dose or potency if occurs. Hepatic impairment. Diabetes. Discontinue if irritation develops. Avoid abrupt cessation. Pregnancy. Nursing mothers: use on the smallest area of skin for the shortest duration.
Pharmacological Class:
Corticosteroid.
Adverse Reactions:
Burning, stinging, rash, redness, itching, paresthesia, contact dermatitis; HPA axis suppression (esp. in children), Cushing's syndrome, hyperglycemia, skin atrophy, secondary infections.
How Supplied:
Crm—45g, 80g
Endocrinology Advisor Articles
- Soluble Klotho Levels Predictive of Kidney Failure in Type 2 Diabetes
- HbA1c Levels Predictive of Liraglutide Treatment Response in T2D
- Clinicians May Be Overtreating Older Patients With Diabetes
- Comorbid and Pharmacologic Factors Increase Risk for Gastrointestinal Disorders in Diabetes
- ADA Updates Guidelines for Cardiovascular Risk Management in Diabetes
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Hormonal Contraceptives May Adversely Affect Psychological Health in Adolescent Girls
- Obesity Can Negatively Effect Liver in Children as Young as 8
- Recommendations Developed on Gender Equity in Medicine
- Intensive Lifestyle Interventions Cut Long-Term Disability in Type 2 Diabetes